Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
Trial details
- Registry ID
- NCT06334133
- Drugs studied
- Cadisegliatin 800 mg BID, Cadisegliatin 800 mg QD
TrialRedline tracks 2 clinical trials sponsored by vTv Therapeutics: 1 Phase 3, 1 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 DiabetesNCT06334133 | Cadisegliatin 800 mg BID, Cadisegliatin 800 mg QD | Active not recruiting | 2027-04Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) SystemsNCT07616206 | Cadisegliatin 800 mg QD | Recruiting | 2027-06Estimated |
Names as written in the registry records.
Before: Not yet recruiting. After: Recruiting.
Before: Apr 2027. After: Jun 2027.
NCT06334133 · vTv Therapeutics
Before: Sep 2026. After: Apr 2027.
Before: Recruiting. After: Active not recruiting.